• 1. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143

Comprehensive Guide to tert-butyl (3R)-3-(2-aminoethyl)piperidine-1-carboxylate (CAS No. 1217629-55-4)

tert-butyl (3R)-3-(2-aminoethyl)piperidine-1-carboxylate (CAS No. 1217629-55-4) is a specialized chiral piperidine derivative widely used in pharmaceutical research and organic synthesis. This compound, featuring a tert-butyl carbamate protecting group and an aminoethyl side chain, serves as a key intermediate in the development of bioactive molecules. Its unique stereochemistry at the 3-position (R-configuration) makes it particularly valuable for asymmetric synthesis and drug discovery.

The growing demand for enantiomerically pure intermediates like tert-butyl (3R)-3-(2-aminoethyl)piperidine-1-carboxylate reflects the pharmaceutical industry's focus on precision medicine. Researchers frequently search for "chiral building blocks for drug synthesis" or "CAS 1217629-55-4 applications," highlighting its relevance in modern medicinal chemistry. This compound's protecting group strategy (Boc-group) allows selective deprotection, enabling sequential functionalization—a hot topic in peptide mimetics and CNS drug development.

From a chemical perspective, 1217629-55-4 exhibits excellent stability under standard conditions while remaining reactive for N-alkylation or amide coupling—frequent search terms among synthetic chemists. Its piperidine scaffold is particularly significant, as this structural motif appears in 20% of FDA-approved small-molecule drugs (2015-2020 data). Current trends show increased interest in "piperidine derivatives for neurological targets" and "Boc-protected amine handling," both directly relevant to this compound.

The tert-butyl (3R)-3-(2-aminoethyl)piperidine-1-carboxylate market has seen steady growth (CAGR 6.2%, 2020-2025) due to rising demand for GPCR-targeted therapeutics. Analytical techniques like chiral HPLC and LC-MS (common optimization queries) are crucial for quality control. Suppliers often emphasize its ≥98% purity and enantiomeric excess (>99% ee), critical parameters for researchers investigating "stereoselective synthesis routes" or "chiral resolution methods."

In drug discovery applications, this compound's primary amine functionality enables diverse derivatization—addressing frequent search phrases like "amine protection-deprotection strategies." Recent publications highlight its use in developing sigma receptor ligands and kinase inhibitors, with particular attention to its role in blood-brain barrier penetration studies—a trending topic in neuropharmacology forums.

Handling CAS 1217629-55-4 requires standard laboratory precautions, though its non-hygroscopic nature simplifies storage compared to other aminoethyl derivatives. Industry discussions often focus on "scaling up chiral intermediates" and "cost-effective Boc protection," reflecting commercial synthesis challenges. The compound's crystalline form (another searched property) enhances processability in large-scale pharmaceutical manufacturing.

Emerging applications include its use in PROTAC linker design (a hot 2023 research area) and bioconjugation chemistry. Patent analysis reveals increasing references to 1217629-55-4 in cancer immunotherapy and neurodegenerative disease research, aligning with Google Scholar's rising "chiral amine drug discovery" citations (42% increase since 2020).

For analytical purposes, tert-butyl (3R)-3-(2-aminoethyl)piperidine-1-carboxylate shows characteristic NMR peaks (δ 1.45 for Boc group) and mass spec fragmentation patterns—frequent troubleshooting topics in chemistry forums. Its solubility profile (soluble in DCM, THF; moderate in ethanol) makes it versatile for diverse reaction conditions, addressing common "amine compound solubility issues" searches.

The future outlook for CAS 1217629-55-4 remains strong, particularly with growing interest in chiral pharmacophores and targeted drug delivery. As pharmaceutical R&D increasingly focuses on stereospecificity (a 2023 ACS Medicinal Chemistry highlight), demand for high-quality (3R)-configured building blocks like this compound will continue rising, especially in fragment-based drug design approaches.

• 158958-41-9(tert-butyl N-ethyl-N-[(piperidin-4-yl)methyl]carbamate)
• 189333-03-7(Tert-butyl 2,9-diazaspiro[5.5]undecane-2-carboxylate)
• 138022-04-5(Tert-Butyl methyl(piperidin-4-ylmethyl)carbamate)
• 236406-22-7(Tert-butyl 4-(aminomethyl)-4-methylpiperidine-1-carboxylate)
• 259180-77-3(tert-butyl 3-(2-aminoethyl)piperidine-1-carboxylate)
• 138022-01-2(1-Piperidinecarboxylicacid, 4-[(dimethylamino)methyl]-, 1,1-dimethylethyl ester)
• 614745-80-1(tert-Butyl 4-((ethylamino)methyl)piperidine-1-carboxylate)
• 144222-22-0(tert-butyl 4-(aminomethyl)piperidine-1-carboxylate)
• 138022-02-3(4-(Methylamino)methylpiperidine-1-carboxylic Acid tert-Butyl Ester)
• 1023595-19-8(Tert-butyl 2,9-diazaspiro[5.5]undecane-9-carboxylate)